Zobrazeno 1 - 10
of 209
pro vyhledávání: ''
Autor:
Xiaoduan Sun, Zhenzhen He, Ruilin Lu, Zhongbing Liu, Sawitree Chiampanichayakul, Songyot Anuchapreeda, Jun Jiang, Singkome Tima, Zhirong Zhong
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Icaritin (ICT), a promising anti-hepatocellular carcinoma (HCC) prenylated flavonoid, is hindered from being applied due to its low water solubility and high lipophilicity in poorly differentiated HCC which is associated with upregulati
Externí odkaz:
https://doaj.org/article/e108c8f065d844dcb87f48b5edafc856
Autor:
Lanqian Su, Huanyu Luo, Yalan Yan, Zhongqiu Yang, Jiaan Lu, Danqi Xu, Linjuan Du, Jie Liu, Guanhu Yang, Hao Chi
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
This review systematically examines gender differences in hepatocellular carcinoma (HCC), identifying the influence of sex hormones, genetic variance, and environmental factors on the disease’s epidemiology and treatment outcomes. Recognizing the l
Externí odkaz:
https://doaj.org/article/c4c044e7c965424cb2182202d4944a7a
Autor:
Yu-Xi Liu, Lu Wang, Cong-Ying Zhang, Kai-Hua Long, Jing Liu, Shuai Liu, Yuan Wang, Ye Li, Yang Liu, Hong Zhang
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Hepatocellular carcinoma (HCC) has been a highly common and pathological disease worldwide, while current therapeutic regimens have limitations. Chebulae Fructus, a common herbal medicine in Asia, has been documented to exert potential
Externí odkaz:
https://doaj.org/article/ff00f073c41b47338374589e2feb220c
Autor:
Xiao Yang, Chen Liang, Li Shao, Wenxuan Cui, Ruobing Ning, Fan Ke, Yue Wang, Peng Gao, Yidi Yin, Qing Li
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundBoth Sophora flavescens (SF) and Astragalus mongholicus (AM) are known for their anti-inflammatory, antifibrotic, and anticancer activities. However, the efficacy, multi-target mechanisms, and therapeutic substances of SF-AM herb pair on th
Externí odkaz:
https://doaj.org/article/ca3811e55bee4879bff2518e930ef31d
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Hepatocellular Carcinoma (HCC) patients often develop resistance to tyrosine kinase inhibitors (TKIs) like sorafenib (SR) and lenvatinib (RR). We established HCC cell lines resistant to these drugs and analyzed the correlation between protein and met
Externí odkaz:
https://doaj.org/article/4bde2a27b2d9485f9868578556a375df
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Hepatocellular carcinoma (HCC) is a common and highly malignant tumor with poor outcomes, especially when it metastasizes. In this report, we present the case of a 64-year-old male patient diagnosed with recurrence and multiple metastases of HCC 7 ye
Externí odkaz:
https://doaj.org/article/144efb2b18784551ae83b8cbb22a38a5
Autor:
Pratibha Pandey, Deena Elsori, Rahul Kumar, Sorabh Lakhanpal, Indra Rautela, Tariq Mohammed Alqahtani, Fuzail Ahmad, Danish Iqbal, Fahad Khan
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Liver cancer is the second leading cause of cancer-related death worldwide. However, treatment options, including surgical resection, transplantation, and molecular drug therapies, are of limited effectiveness. Recent studies have demonstrated that s
Externí odkaz:
https://doaj.org/article/6e66d616db464876a0d4578a6b6b8cba
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: This study will explore the therapeutic value of traditional Chinese medicine (TCM) in Hepatocellular Carcinoma (HCC) through meta-analysis, combined with network pharmacology analysis.Methods: The results of randomized controlled trials
Externí odkaz:
https://doaj.org/article/57e055f02fb54c8fa1f3d62473ba83a8
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
The study aimed to investigate the potential of traditional Chinese medicine (TCM) in reducing the risk of macrovascular invasion (MVI) in Chinese patients with hepatocellular carcinoma (HCC). This retrospective analysis involved 2,267 HCC patients t
Externí odkaz:
https://doaj.org/article/50bb8dd799764ad4a08705a9056b6a06
Autor:
Yue Chen, Yutao Wang, Jin Lei, Bowen Chen, Xinfeng Zhang, Liangzheng Chang, Zhangli Hu, Yun Wang, Yinying Lu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background and aims: Tyrosine kinase inhibitors (TKIs) combined with programmed cell death protein-1 (PD-1) have significantly improved survival in patients with unresectable hepatocellular carcinoma (uHCC), but effective biomarkers to predict treatm
Externí odkaz:
https://doaj.org/article/0e71c5bc10de423cb5be3e5aa34acd2f